Office of the Registrar or Lobbying of BC

Menus

  • Menus

www.lobbyistsregistrar.bc.ca

  • www.lobbyistsregistrar.bc.ca

Designated Filer menu

  • Registry Search Tools
    • 12-Month Lobbying Activity Search
    • Advanced Registry Search
  • Reporting Tools
    • Recent Registrations
    • Recent Lobbying Activity Reports by Posted Date
    • Government Funding Report
    • Gifts to Public Office Holders Report
    • Listing of All Lobbyists and Senior Officers
    • Listing of Senior Public Officer Holders who are in Lobbying Activity Reports
    • Listing of Organizations Clients and their Direct Interests
  • Lobbying Statistics
    • Active Lobbyists and Registrations by Type
    • Ministries/Provincial Entities in Active Registrations
    • Ministries/Provincial Entities in Lobbying Activity Reports
    • Lobbying Activity Reports by Reporting Period
    • Subject Matter in Active Registrations
    • Subject Matter in Lobbying Activity Reports
    • Intended Outcomes in Active Registrations
    • Intended Outcomes in Lobbying Activity Reports
  • Help
    • LTA Guidance Documents
    • Using the Registry
    • Legislation
    • LTA Frequently Asked Questions
    • Contact Us
  • Sign In

You are here:

  1. Registry Dashboard

 

Subject matter details

Innovative Medicines Canada (Medicaments novateurs Canada)


Registration: 72 of 72 (2026-04-16 to present)

Details Regarding the Identified Subject Matter
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Advocate for the adoption of innovative payer agreements at the pan-Canadian level incorporating real world evidence.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Advocate for workload capacity building and the acceleration of the work of the pan-Canadian Pharmaceutical Alliance which is an intergovernmental collaboration currently chaired by BC.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Advocate regarding provincial government funding decisions for British Columbia’s PharmaCare program, including budget allocations.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Finances and Budgets, Health
Advocate regarding provincial policies governing the assessment, reimbursement and formulary listing of medicines in BC.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Discussion on the Pharmaceutical Care Management Strategy.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Engage with the BC government to improve access to innovative medicines and vaccines, and advance collaborative, data-driven procurement approaches that enhance patient outcomes, strengthen BC’s life sciences sector and promote health system sustainability.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Government Procurement, Health
Engage with the government of British Columbia on the annual Provincial Budget preparation and submission.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Economic Development and Trade, Finances and Budgets, Health
Highlight the contribution of IMC membership to health outcomes and economic sustainability in British Columbia, and advocate for provincial government policy initiatives and investment decisions (e.g., R&D commercialization incentives, infrastructure support) to support the life sciences sector as a driver of long-term economic growth in the province.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health, Science and Technology
Policy measures to ensure security of drug supply in BC and Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations and their impact on patient access and economic growth in British Columbia.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Economic Development and Trade, Health, Intellectual Property, International Relations, International Trade, Science and Technology